ATE475428T1 - Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen - Google Patents

Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen

Info

Publication number
ATE475428T1
ATE475428T1 AT01933358T AT01933358T ATE475428T1 AT E475428 T1 ATE475428 T1 AT E475428T1 AT 01933358 T AT01933358 T AT 01933358T AT 01933358 T AT01933358 T AT 01933358T AT E475428 T1 ATE475428 T1 AT E475428T1
Authority
AT
Austria
Prior art keywords
cells
autoreactive
blocking
destruction
polypeptide
Prior art date
Application number
AT01933358T
Other languages
English (en)
Inventor
Yang Liu
Pan Zheng
Xue-Feng Bai
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of ATE475428T1 publication Critical patent/ATE475428T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
AT01933358T 2000-03-29 2001-03-29 Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen ATE475428T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19281400P 2000-03-29 2000-03-29
PCT/US2001/040390 WO2001072325A1 (en) 2000-03-29 2001-03-29 Methods of blocking tissue destruction by autoreactive t cells

Publications (1)

Publication Number Publication Date
ATE475428T1 true ATE475428T1 (de) 2010-08-15

Family

ID=22711138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933358T ATE475428T1 (de) 2000-03-29 2001-03-29 Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen

Country Status (8)

Country Link
EP (1) EP1267909B1 (de)
JP (1) JP2004500110A (de)
AT (1) ATE475428T1 (de)
AU (2) AU5979201A (de)
CA (1) CA2404340C (de)
DE (1) DE60142684D1 (de)
DK (1) DK1267909T3 (de)
WO (1) WO2001072325A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030106084A1 (en) 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
NZ603196A (en) * 2010-04-28 2014-07-25 Oncolmmune Inc Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2014011987A1 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating car t cells
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
JP6736540B2 (ja) 2014-07-21 2020-08-05 ノバルティス アーゲー Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
CN107207597A (zh) * 2014-11-06 2017-09-26 儿研所儿童医学中心 用于癌症和自身免疫疾病的免疫疗法
AU2016258084B2 (en) * 2015-05-07 2020-01-30 Oncoimmune, Inc. Use of CD24 for lowering low-density lipoprotein cholesterol levels
US10639350B2 (en) 2015-08-10 2020-05-05 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using CD24
CA3012466A1 (en) * 2016-02-02 2017-08-10 Oncoimmune, Inc. Use of cd24 proteins for treating leptin-deficient conditions
SG11201908077XA (en) * 2017-03-07 2019-09-27 Oncoimmune Inc Methods of use of soluble cd24 for treating systemic lupus erythematosus
US20200181235A1 (en) * 2017-05-15 2020-06-11 Oncoimmune, Inc. Methods of use of soluble cd24 for neuroprotection and remyelination
AU2019284911B2 (en) 2018-06-13 2026-04-09 Novartis Ag BCMA chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
EP1267909A1 (de) 2003-01-02
JP2004500110A (ja) 2004-01-08
WO2001072325A9 (en) 2003-02-20
CA2404340C (en) 2012-10-16
EP1267909A4 (de) 2006-05-03
DE60142684D1 (de) 2010-09-09
CA2404340A1 (en) 2001-10-04
AU2001259792B2 (en) 2005-12-22
WO2001072325A1 (en) 2001-10-04
AU5979201A (en) 2001-10-08
DK1267909T3 (da) 2010-11-08
EP1267909B1 (de) 2010-07-28

Similar Documents

Publication Publication Date Title
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
DE60142684D1 (de) Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen
Jones et al. Histogenesis of Kaposi's sarcoma in patients with and without acquired immune deficiency syndrome (AIDS).
EP0751992A4 (de) Vaskularer endothelialer wachstumsfaktor 2
JPH04507195A (ja) 腫瘍壊死因子結合リガンド
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
EP1140175A4 (de) Antikörper gegen verkürzten vegf-d und deren verwendungen
KR927003816A (ko) Cd3에 대한 항체
EP0837696A4 (de) Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
DE69309472D1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
ATE506076T1 (de) Medizinische verwendung von anti-cs1 antikörpern
MA28418B1 (fr) Anticorps liant un recepteur de l'interleucine 4
DK161015C (da) Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop
DE68925226D1 (de) Monoklonale Antikörper
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
EP1003552A4 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGENE ZUR HEMMUNG VON T-ZELL AKTIVIERUNG UND WACHSTUM
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
NO985904L (no) TIE-2-reseptorligander (TIE-ligand-3, TIE-ligand-4), samt anvendelse derav
AR003941A1 (es) Anticuerpos monoclonales humanos neutralizadores de hiv-1
Moolten et al. Induction of antibodies against carcinogenic polycyclic aromatic hydrocarbons
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
EA199800352A1 (ru) ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties